Towards the identification of causal genes for age-related macular degeneration

Fei-Fei Cheng^{1,2,3,5}, You-Yuan Zhuang^{1,2,5}, Xin-Ran Wen^{1,2}, Angli Xue⁴, Jian Yang^{3,4,6,*}, Zi-Bing Jin^{1,2,6,*}

¹Division of Ophthalmic Genetics, The Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China;

²National Center for International Research in Regenerative Medicine and Neurogenetics, National Clinical Research Center for Ophthalmology, State Key Laboratory of Ophthalmology, Optometry and Visual Science, Wenzhou, 325027 China;

³Institute for Advanced Research, Wenzhou Medical University, Wenzhou 325035, China;

⁴Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, 4072, Australia;

⁵These authors contributed equally.

⁶These authors jointly supervised this work.

*Correspondence: Zi-Bing Jin <jinzb@mail.eye.ac.cn> or Jian Yang <jian.yang.qt@gmail.com>.

Abstract

Age-related macular degeneration (AMD) is a leading cause of visual impairment in ageing populations and has no radical treatment or prevention. Although genome-wide association studies (GWAS) have identified many susceptibility loci for AMD, the underlying causal genes remain elusive. Here, we prioritized nine putative causal genes by integrating expression quantitative trait locus (eQTL) data from blood ($n = 2,765$) with AMD GWAS data (16,144 cases vs. 17,832 controls) and replicated six of them using retina eQTL data ($n = 523$). Of the six genes, altering expression of *cnn2*, *sarm1* and *bloc1s1* led to ocular phenotype, impaired vision and retinal pigment epithelium (RPE) loss in zebrafish. Essential photoreceptor and RPE genes were downregulated in *cnn2*- and *sarm1*-knockdown zebrafishes. Through integration of GWAS and eQTL data followed by functional validation, our study reveals potential roles of *CNN2*, *SARM1* and *BLOC1S1* in AMD pathogenesis and demonstrates an efficient platform to prioritise causal genes for human complex diseases.

Introduction

Age-related macular degeneration (AMD) is an incurable blinding disorder caused by dysfunction of the retinal pigment epithelium (RPE) and progressive loss of photoreceptors in the macula¹. It results in visual impairment of central vision and disability of daily life activities, such as reading, walking and face recognition. The prevalence of AMD is 8.69% in the age range of 45-85 years globally, and it is projected to affect 196 million people worldwide in 2020². As such, AMD is highly endorsed as a major health and social problem for both individuals and communities, especially in elderly populations³.

AMD is one of the most genetically well-defined complex diseases. Genome-wide association studies (GWAS) with increasing sample sizes have identified 52 susceptibility loci which together explain more than 50% of the heritability of liability⁴⁻⁶. These findings provide important clues for understanding the genetic architecture of the disease, but the causal genes at those susceptibility loci and underlying mechanisms remain largely unclear. For example, a nonsynonymous variant, *CFH* p. Arg1210Cys (allele frequency = 0.00017 in ExAC), increases AMD risk by >20-fold⁷, but there has been no evidence showing its functional impact on the regulation of gene expression, structural and functional integrity of the protein-coding region, or interplay with the genes nearby⁸. This is partly because of linkage disequilibrium (LD) between single-nucleotide polymorphisms (SNPs) and causative variants that GWAS mapping resolution⁹. This could also be the reason that the trait-associated variants, especially those residing in non-coding regions, exert an impact on gene expression through distal regulation¹⁰.

With the availability of data from large-scale GWAS⁵, expression quantitative trait locus (QTL) studies¹¹ and advanced integrative statistical methods^{12,13}, we sought to test the hypothesis that genetic variants at some of the susceptibility loci affect the risk of AMD through genetic regulation of transcriptional levels. We used the summary-data-based Mendelian randomization (SMR) here¹², which features the statistical power because of the flexibility to utilize GWAS and eQTL data from two independent studies. We subsequently used heterogeneity in dependent instruments (HEIDI) approaches to distinguish causality/pleiotropy (i.e., the same causal variant(s) affecting AMD susceptibility and the expression level of a gene) from linkage (i.e., two distinct causal variants in LD, one affecting AMD susceptibility and the other affecting certain gene expression). This analytical framework has been successfully used in various common diseases, such as diabetes, autoimmune diseases, and psychiatric disorders^{14,15}, and is for the first time used in ocular diseases in this study.

We then established an experimental scheme that utilized morpholino oligonucleotide (MO)-induced knockdown and/or mRNA overexpression zebrafish as an animal model to assay the putative causal genes identified by the above integrative analysis (**Figure 1**). Valid procedures were designed to provide morphological and functional assessments of the zebrafish ocular phenotypes, thereby demonstrating the functional relevance to AMD pathogenesis for these prioritised genes. Moreover, the research workflow that combines integrative analysis of large-scale data in humans and functional validation in zebrafish is

general and can be used as a new paradigm to efficiently and effectively highlight susceptible genes for human complex diseases and then provide insights for additional prospective therapeutic applications.

Fig. 1 Schematics of study design. First, blood eQTL and AMD GWAS data were integrated through SMR and HEIDI to identify expression–phenotype associations before replications in retina or other 48 human tissues in GTEx. Then, functional experiments were conducted in zebrafish to measure ocular sizes, light-induced behavioural patterns, qPCR of photoreceptors and RPE genes and retinal immunostaining to validate the prioritised genes.

Results

Associating gene expression with AMD risk by an integrative analysis

To prioritize genes whose expression levels are associated with AMD risk, we used SMR¹² to test if a variant has a joint association with AMD risk and the expression level of a gene, using GWAS and eQTL summary data. The GWAS summary data were derived from a study of the International AMD Genomics Consortium with 16,144 AMD cases vs. 17,832 controls⁵. The eQTL summary data were generated by the Consortium for the Architecture of Gene Expression (CAGE) from a study of 36,778 gene expression probes in peripheral blood of 2,765 individuals¹¹. All the individuals were predominantly of European ancestry, and both datasets are publicly available (URLs). And the test was performed for each of the genes with at least an eQTL at $P_{\text{eQTL}} < 5\text{e-}8$ (Methods).

87
88 In total, we identified 16 genes (tagged by 21 probes) at a genome-wide significance level
89 ($P_{smr} = 5.9 \times 10^{-6}$, correcting for 8459 tests, i.e., 8459 probes with at least an eQTL at $P_{eQTL} < 5e-8$)
90 (**Supplementary Table 1**). We then employed the HEIDI method¹² to reject SMR associations due to
91 linkage (removing probes with $P_{HEIDI} < 0.05$) (**Methods**). And the LD information, required for the HEIDI
92 test, was computed from genotype data of randomly selected 20,000 individuals from European ancestry in
93 the UK Biobank¹⁶. Consequently, 9 genes (tagged by 12 probes) were retained (**Table 1**), and some of
94 which, including *BLOC1S1*, *PILRB*, and *TMEM199*, have been reported in a recent study that used a
95 different strategy to integrate AMD GWAS with retinal eQTL data¹⁷. We found that 58.3% of the identified
96 probes were not tagging the closest genes to the top associated GWAS signals, consistent with the
97 observations from previous studies^{10,12}. The eQTL variants of all the prioritised genes were common with
98 minor allele frequencies (MAF) ranging from 0.11 to 0.49. It is of note that the association of rs7212349
99 (i.e., the top associated variant for gene *SARM1* with $P_{eQTL} = 1.0e-22$) with AMD ($P_{GWAS} = 1.8e-7$) did not
100 reach the conventional genome-wide significance threshold, suggesting a gain of power in gene discovery
101 by leveraging eQTL data, in line with previous work¹².

Table 1 Putative causal genes for AMD identified from SMR & HEIDI analysis using the blood or retina eQTL data.

Probe ID	Chr	Gene	topSNP	A1	A2	Freq	CAGE-Blood				Retina
							P_{GWAS}	P_{eQTL}	P_{SMR}	P_{HEIDI}	P_{SMR}
1685534	7	PILRB	rs7792525	G	A	0.19	1.09e-08	1.72e-23	7.01e-07	0.121	3.88e-08
1807712	7	PILRB	rs1964242	A	G	0.19	7.07e-09	4.41e-76	3.31e-08	0.317	2.68e-08
1723984	7	PILRB	rs73401450	C	G	0.19	1.07e-08	3.28e-205	1.89e-08	0.183	3.83e-08
1768754	7	PILRB	rs61735533	A	G	0.19	1.60e-08	7.93e-255	2.48e-08	0.257	5.37e-08
1773395	12	BLOC1S1-RDH5	rs56108400	T	G	0.24	2.36e-08	8.3e-82	8.31e-08	0.407	2.65e-06
1773395	12	BLOC1S1-RDH5	rs56108400	T	G	0.24	2.36e-08	8.3e-82	8.31e-08	0.407	7.64e-01
1748481	17	TMEM199	rs708100	G	A	0.49	2.50e-08	1.86e-18	2.56e-06	0.351	1.94e-04
1746265	17	SARM1	rs7212349	T	C	0.45	1.81e-07	1.00e-22	4.09e-06	0.128	4.39e-03
2043615	17	C17orf90	rs11150803	A	C	0.47	4.36e-09	6.77e-81	2.03e-08	0.012	6.74e-01
1805131	17	C17orf90	rs9910935	T	C	0.47	1.71e-09	1.13e-17	8.40e-07	0.139	8.27e-01
1708486	19	CNN2	rs3087680	C	A	0.11	4.57e-08	3.26e-56	2.38e-07	0.760	7.80e-05
1743205	19	ABCA7	rs3087680	C	A	0.11	4.57e-08	4.44e-136	9.33e-08	0.737	7.51e-02
1796316	20	MMP9	rs3918261	G	A	0.14	1.02e-09	9.78e-34	4.98e-08	0.196	3.06e-02

102 Chr represents chromosome; A1 is the effect allele; Freq is frequency of the effect allele in the reference sample.

103 Note: *BLOC1S1-RDH5* is an integrated probe in CAGE, but separated probes in EyeGex-Retina.

Replication of the SMR associations in retina and other tissues

Given possible tissue-specific genetic effects, we replicated SMR associations of the nine significant genes in retina. The retinal eQTL summary data were retained from 523 postmortem subjects¹⁷, available in the Eye Genotype Expression (EyeGex) database (**URLs**). Six of the nine genes were replicated at $P_{smr} = 5.6 \times 10^{-3}$ (i.e., 0.05/9), a relatively high replication rate given the small sample size of the EyeGex data (**Table 1** and **Supplementary Figure 1**). However, for some of the replicated genes, the eQTL effects were significantly different, even in opposite directions, between the retina and CAGE-blood. For instance, the estimated effect of *SARM1* on AMD risk was 0.301 (standard error (SE) = 0.065 and $P_{eQTL} = 4.1 \times 10^{-6}$) in CAGE-blood, consistent in several other tissues (see **Supplementary Figure 1**), but was -0.351 (SE = 0.123 and $P_{eQTL} = 4.4 \times 10^{-3}$) in retina, suggesting that a strong tissue-specific effect and the importance to replicate and interpret discovery results in disease-relevant tissue(s).

It is unclear whether AMD is a localized disease (occurring only in affected retinas) or an ocular manifestation of a systemic process, since risk factors such as cigarette smoking, nutrition, and cardiovascular disease have a significant impact on disease progression¹⁹⁻²³. Thus, we conducted SMR analysis for the nine genes in a wider range of tissues available in the GTEx project (**Supplementary Figure 1**). Intriguingly, the results showed that *PILRB*, a key activator in immune function, is significant across all 48 human tissues with effect sizes ranging from 0.081 (in retina) to 0.249 (in whole blood), implying that systemic immune pathways may be involved in AMD pathogenesis. In fact, *PILRB* is not an exception; all the nine genes were significant in at least two tissues and did not display obvious tissue-specific effects except for *SARM1* shown above, consistent with the results from previous studies that cis-eQTL effects are largely consistent across tissues²⁴. Our results also suggest that the across-tissue replication rate depends heavily on the size of replication sample, supporting that using blood eQTL data from large samples gains power for gene discovery.

Supplementary Figure 1: Heatmap of SMR results of the nine prioritised genes in multiple tissues. Each row represents a prioritised gene, and each column represents a tissue. $-\log(P\text{-value}_{\text{SMR}})$ is plotted in white-purple scale. The purple color indicates more significant and the white means less significant. Each tile with a number available indicates it reaches the significant threshold $5.6\text{E-}3$ (correcting for 9 tests), with the number being the estimated SMR effect. Note that the overall mean SMR p-value is decreasing towards top and right. Replication in retina is highlighted by a red rectangle.

Knockdown of *cnn2* or *sarm1* led to ocular abnormalities in zebrafish

To validate the functional relevance of the prioritised genes to AMD pathogenesis, we sought an animal model that is amenable to manipulating gene expression and that can reliably evaluate ocular phenotypes. We chose zebrafish also because it has been extensively used to model ocular and other disorders²⁵⁻²⁷. Accounting for sequence homology between human and zebrafish, we obtained 4 of the 9 prioritised genes (*CNN2*, *SARM1*, *BLOC1S1* replicated at $P_{\text{SMR}} < 5.6\text{E-}3$ and *MMP9* at $P_{\text{SMR}} < 0.05$ using the retina eQTL data; **Table 1**) with orthologue similarity above 60%, reported by either Ensembl or GeneCards, for functional follow-up (URLs, **Supplementary Table 2**). Then, MO technology, blocking the translation process of a certain mRNA, was used to knock down the corresponding gene. We observed that

downregulation of *cnn2* and *sarm1* at doses of 6 ng MO and 1.0 ng, respectively, led to obvious decreases in axis length (by 32.5% and 21.3%, respectively) and eye area (by 48.5% and 28.5%, respectively), whereas suppression of *mmp9* and *bloc1s1* showed no significant difference at 3 days post fertilisation (dpf) (**Figure 2** and **Supplementary Figure 2**).

To further confirm the results, we conducted dose-dependent and rescue experiments. We found that in comparison to the control, eye sizes of *cnn2*-MO morphants were smaller and the degree was inversely proportional to the MO dose (from 4.0 to 6.0 ng) without higher mortality (**Supplementary Figure 3**). For the *sarm1*-MO morphants, abnormal ocular phenotypes occurred when the MO dose was extremely low (0.50 ng), and the impact accumulated when the dose increased (from 0.50 to 4.0 ng), indicating that ocular development might be sensitive to the *sarm1* expression level (**Supplementary Figure 4**). Importantly, rescue of the smaller eyes was achieved in the mRNA and MO co-injected larvae for both genes (**Figure 3a,d**). Axial length was recovered by 95.8% for *sarm1*-MO and 91.0% for *cnn2*-MO (**Supplementary Note 1**). This study provides evidence for potential roles of *CNN2* and *SARM1* in ocular development and disease-causing mechanisms.

Fig. 2 Phenotypes of *cnn2*-, *sarm1*-, *mmp9*-, *bloc1s1*-deficient zebrafish. (a) Lateral view of whole bodies. (b) Magnified lateral view of zebrafish eyeballs exhibits apparent decreases in eye area for *cnn2*- and *sarm1*-deficient fishes. (c) Vertical view of eyeballs showing shorter axial length in *cnn2* and *sarm1* knockdown larvae. (d) Quantification of eye area, axial length and ratio of axial length and body length, respectively. Bar plots are shown as the mean $\pm$ s.e.m. T-test was performed between each group and the standard control. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. N=10 for each group.

Knockdown of *cnn2* or *sarm1* led to functional impairment in zebrafish

We then used a visual motor response (VMR) assay to evaluate the visual condition at the behavioural level 5 dpf. According to a standard protocol²⁸, zebrafish were placed in a 96-well plate and the locomotor response to light alteration was monitored. We found that, for *CNN2*, three groups, including the uninjected control, standard MO control and *cnn2* mRNA, had a brief spike at approximately 0.20-0.22 of motor activity for ON response and 0.12-0.15 for OFF response (**Figure 3b, 3c**). In comparison, the response of the *cnn2* MO-injected group was weakened and delayed, with the peak dramatically decreasing by 61.9% for lights-ON and by 78.6% at 20 s later when lights-OFF. Of note, augmentation of *cnn2* mRNA with MO morphants could save a visual response to 0.16 for lights-ON (recovering by 61.5%); when lights-OFF, their motor activities were intensified to 0.08 (recovering by 45.5%), and the baseline was notably improved. Actually, functional recovery relied on a sufficient dose of injected mRNA. Our pre-experiment suggested that only partial rescue of visual function could be realized when injecting less *cnn2* mRNA (**Supplementary Figure 5**). In addition, the *SARM1* group showed similar results but with more severe visual impairment (**Figure 3e,f**). Notably, simple injection of *sarm1* mRNA seemed to slightly promote the OFF response, implying an underlying therapeutic target. Taken together, the results of the visual function assays further elucidate the reduction in visual motor activities specifically caused by forced downregulation of *cnn2* or *sarm1*, indicating their essential roles in maintaining normal visual function.

Fig. 3 Morphological and functional effects of knockdown and rescue of *cnn2* and *sarm1* in zebrafish larvae. (a, d) The scatter plots of body length and eyeball axial length. The *cnn2* or *sarm1* MO group (labelled by red triangle) was clearly separate from the other groups, showing a reduction in eye size. In addition, injecting corresponding mRNA (labelled by green dot) could rescue the reduced ocular size. (b, c, e, f) VMR testing for ON and OFF responses. Lights-ON or lights-OFF stimuli occurred at 30 s. Real-time motor activities of zebrafish were recorded by lines. The area under the curve reflected the sum of motor activities during the 150 s. The responses of the *cnn2* or

sarm1 MO group (labelled by red line) were dramatically weakened and could also be saved by injecting mRNA (labelled by green line).

Knockdown of *cnn2* or *sarm1* downregulated the expression of photoreceptor and RPE signature genes

Considering the potential role of *CNN2* and *SARM1* in AMD pathophysiology, we sought to test the hypothesis whether visual impairment could be attributed to defects of vital photoreceptor or RPE genes. Thus, we conducted reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis to measure the expression levels of retinal signature genes: *rhodopsin*, four kinds of cone opsins (*red*, *green*, *blue*, and *uv*) and RPE-specific gene *rpe65a*^{29,30}. For the *cnn2* 6.0 ng MO group and the *sarm1* 1.0 ng MO group, all these genes showed dramatic decreases compared to the standard MO control; *rhodopsin* decreased by 117.1-fold and 12.6-fold respectively, so as to cone opsin (*green opsin* by 797.5-fold and 13.6-fold, *blue opsin* by 279.8-fold and 10.4-fold, *red opsin* by 107.4-fold and 8.0-fold, and *uv opsin* by 19.2-fold and 10.8-fold), and *rpe65a* (by 7.5-fold and 3.6-fold) (**Figure 4**). However, regarding the *mmp9* 6.0 ng MO group, the expression levels of all six genes slightly increased by 1.2-2.4 folds. Combined with the results above, the transcriptional reduction of signature genes in RPE and photoreceptors, caused by downregulation of *cnn2* or *sarm1*, is in line with ocular abnormality and visual behaviour impairments. Since opsin gene expression is a determinant factor for photoreceptor degeneration³¹⁻³³, we hypothesize that downregulation of *CNN2* and *SARM1* are likely involved in photoreceptor degeneration during the pathogenic process of AMD.

Fig. 4 Real-time qPCR of photoreceptor and RPE genes in the MO zebrafish oculus. The x axis

represents photoreceptor and RPE signature genes, and the y axis represents the $\log_{10}(\text{relative expression})$. Centripetal bars indicate downregulation, and centrifugal bars indicate upregulation. The *cnn2*- and *sarm1*- MO groups revealed relatively low expression for all gene markers, whereas the *mmp9* group showed a slight increase. The bar plot is shown as the mean $\pm$ s.e.m.

Knockdown of *cnn2* or *sarm1* disrupted RPE in zebrafish

In addition to the alteration of photoreceptors and RPE at transcriptional level, we investigated the retinal morphological consequences of the knockdown by cryosection and immunostaining to further verify the functional relevance of *CNN2* and *SARM1* with AMD pathogenesis. Using DAPI for nuclear staining, zpr-1 for cones, zpr-2 for RPE and zpr-3 for rods, we found that laminations were basically intact in both the *cnn2* 6.0 ng MO group and the *sarm1* 1.0 ng MO group (**Figure 5**). For the *cnn2* 6.0 ng MO group, staining of cones and rods showed no apparent difference from the standard control, but RPE displayed obvious disorganization and cell loss. For the *sarm1* 1.0 ng MO group, staining of RPE also demonstrated significant deficiency, with most rods disrupted (**Supplementary Figure 6**), whereas cones remained complete. In fact, a prior experiment of the *sarm1* 6.0 ng MO group observed severe lamination disruption, indicating that extreme insufficiency of *sarm1* has a severely adverse impact on ocular development (**Supplementary Figure 7**). Altogether, for both *cnn2* and *sarm1*, RPE were morphologically injured, which is in accordance with a well-accepted understanding that degeneration of RPE is a fundamental trigger of the cascade of events resulting in AMD pathology³⁴. However, photoreceptors seemed not significantly affected. A likely hypothesis is that, in a certain condition, functional changes might precede morphological changes. That is, in the developmental stage, a small number of healthy RPE tissues could burden delivering oxygen and metabolites, where photoreceptors maintain morphological normality but are gradually functionally injured due to downregulation of *cnn2* or *sarm1* and photoreceptor core genes, then cumulative damage tips the balance and consequently leads to degeneration³⁴.

Fig. 5 Retinal architecture of *cnn2*- and *sarm1*-deficient morphants. Nuclear layers were stained by DAPI in grey, and each group showed intact lamination. zpr-1, zpr-2 and zpr-3 were stained in purple for each column. (a) Signals of zpr-1 and zpr-3 in the *cnn2* MO 6.0 ng group were detected at relatively normal levels, but the signal of zpr-2 was much lower compared with the standard control. (b) Signals of zpr-3 and zpr-2 were distributed significantly less in the out layer of retina for the *sarm1* MO 1.0 ng group, and zpr-1 remained intact.

Overexpression of *bloc1s1* resulted in mild impaired ocular phenotypes in zebrafish

Given the significant SMR associations of *BLOC1S1* in both discovery and replication analyses where the effect size was positive in retina and negative in blood, we assumed that GWAS loci in *BLOC1S1* affect the risk of AMD by upregulating its expression. Therefore, we injected an additional zebrafish group with *bloc1s1* mRNA. Compared to controls, smaller eyes were observed in *bloc1s1*-overexpressing fishes (Figure 6a) with axial length decreased by 7%. For the visual behaviour, the ON response was not apparently affected, but impairment of the OFF response was observed in the *bloc1s1* mRNA-injected group with the peak of OFF response declined by 59.1% (Figure 6b,c). Immunostaining results showed that disruption of cones, rods and RPE in *bloc1s1*-overexpression group occurred (Figure 6d) but more than one half of staining repetition had no notable difference in comparison to the standard control (Supplementary Figure 8). In terms of qPCR, however, rod gene was down-regulated by 1.4-fold ($P = 5.4e-4$) and uv cone gene was up-regulated significantly by 1.3-fold ($P = 0.025$) but other retinal genes

remained same (**Supplementary Figure 9**), likely in the early stage of degeneration since a previous study showed that aggregation of S-opsin (short-wavelength cone opsin, including uv opsin) is accompanied by the onset of cone degeneration through activating endoplasmic reticulum (ER) stress in a murine model³¹. Overall, impaired ocular phenotypes were caused by *bloc1s1*-overexpressing, but the impairment was milder than that in the knockdown groups above.

Despite that the detrimental effects of overexpression of *bloc1s1* were moderate, the phenotypic results in zebrafish were in line with the estimated SMR effect in retina rather than that in blood. Here, the positive SMR effect means that increased expression level of a gene is associated with increased phenotype (or disease risk) and vice versa. The estimated SMR effect of *BLOC1S1* was in positive and those of *CNN2* and *SARM1* were negative, predicting that increased expression level of *BLOC1S1* and decreased expression levels of *CNN2* and *SARM1* are associated with increased AMD risk. In a word, the prediction from SMR and HEIDI analysis was validated in zebrafish that knockdown of *cnn2* and *sarm1* and overexpression of *bloc1s1* caused ocular abnormalities.

Fig. 6 Phenotypes of *bloc1s1*-overexpression zebrafish larvae. (a) The bar plot of axial length. The *bloc1s1*-overexpression group showed a slight but significant reduction in ocular sizes. (b, c) The VMR testing for ON and OFF responses. The ON response was not apparently affected, but impairment of the OFF response was observed in the *bloc1s1* mRNA-injected group. (d) Immunostaining of *bloc1s1*-mRNA zebrafish retinas showed apparently low expression for zpr-1, zpr-

2 and zpr-3.

Discussion

In this study, we aimed to shed light on the biological knowledge expected from integrated analysis of AMD GWAS and eQTL summary data. Initially, we identified 9 putative causal genes for AMD using the SMR and HEIDI methods based on a blood eQTL dataset (Table 1), and subsequently replicated 6 of the 9 genes using a retina eQTL dataset (Table 1 and Supplementary Figure 1). We also tested the 9 genes in 48 other tissues using the GTEx eQTL data and showed that the across-tissue replication rate depended heavily on the size of replication sample (Supplementary Figure 1). We carried 4 of the 9 genes forward for functional assay in zebrafish and for the first time demonstrated the functional relevance of *CNN2*, *SARM1* and *BLOC1S1* to AMD. Injection of respective *cnn2* MO, *sarm1* MO and *bloc1s1* mRNA in zebrafish larvae exhibited different degrees of ocular defects (Figures 2 and 6), vision loss (Figures 3 and 6), relatively low transcription of essential photoreceptor and/or RPE genes (Figure 4) and RPE degeneration (Figures 5 and 6). Importantly, knockdown-induced phenotypes could be rescued by augmentation of corresponding mRNA (Figure 3), indicating the potential as targets to design new treatments. Finally, the phenotypic effects of alternating transcription of the prioritised genes in zebrafish were in line with the directions of estimated SMR effects in human retinas. All these results provide strong evidence supporting the potential role of *CNN2*, *SARM1* and *BLOC1S1* in AMD pathogenesis.

There is no denying that the study has some limitations. First, we used a large blood eQTL data set ($n = 2,765$) for discovery and a relatively small retina eQTL data set ($n = 523$) for replication, following the suggestion from a recent study¹⁴. This strategy would have missed genes with a cis-eQTL effect in retina but not in blood. However, we considered that if cis-eQTL effects are similar across tissues^{18,24}, using a blood eQTL data set of large sample size could increase the power of gene discovery in comparison to using a retina eQTL data set of small sample size. In addition, blood is much more accessible than retina so that the growth of eQTL data from blood is expected to be faster than that from retina, suggesting that the power of our analysis strategy could be substantially improved in the future by leveraging blood eQTL data sets with sample sizes of orders of magnitude larger than that used in this study³⁵.

Second, zebrafish is an ideal but not perfect animal model. AMD is an age-related disease. However, zebrafish larvae were studied instead of elder zebrafish because the most efficient duration of MO-mediated knockdown effects is the first two or three days of development, and efficiencies decrease later³⁶, rendering it difficult to observe age-related morphological and functional changes. Generating a primate AMD model is the most scientifically valid since humans or primates are the only mammals with a macula and foveal centralis, where AMD manifests, but it is extremely challenging in particular with respect to costs and time scale of the experiment. Instead, an important role of the zebrafish models is to serve as an efficient screening test to narrow down the most plausible causal genes through our comprehensive evaluation approaches. And the robust ocular changes of the prioritised genes, even in larvae time, should

not be underestimated. It is acknowledged that individual SNPs generally confer small effects on gene expression¹¹, but MO interventions dramatically eliminate transcriptional levels, resulting in more severe and noticeable phenotypes. Moreover, accumulating evidence indicates that the origins of age-related disorders occur during foetal life^{37,38}, and AMD should not be an exception.

Third, the genetic mechanisms of gene regulation and the relationship of gene regulation to AMD manifestation remain a mystery. Hypotheses of non-coding SNPs that influence gene expression include transcriptional, posttranscriptional, or posttranslational process⁹, such as non-coding RNA function or histone modification, allowing for more specific regulatory mechanistic studies. Of note, it is more important to identify the causal gene than the causal variant because the ultimate goal is to identify the causal gene, which can correspond to multiple causal variants. A mass of downstream research is required to understand the underlying molecular mechanisms. Intriguing clues include compelling biology such as inflammatory response and lipid metabolism and underlying overlapping pathophysiology with other age-related diseases for genes such as *CNN2*, *PILRB* and *ABCA7* that are also located at risk loci for late onset Alzheimer's disease (AD) (**Supplementary Table 3** for the description of each prioritised gene).

In summary, we performed an integrative data analysis that efficiently pinpointed novel susceptibility genes for AMD, and demonstrated the functional relevance of *CNN2*, *SARM1* and *BLOC1S1* to the disease using zebrafish models. The gene discovery procedure, combining statistical analysis of large-scale data and experimental validation, can be applied to other complex disorders to fill the knowledge gaps between genetic variants and phenotypes.

Online Methods

Data used for the integrative analysis

The GWAS summary data used in this study were derived from the latest and largest AMD GWAS meta-analysis⁵ (see URLs section), consisting of 16,144 advanced AMD patients and 17,832 controls of predominantly European ancestry. The total number of SNPs was up to 12 million. The SNP effects were expressed as log odds ratios. Because the SNP allele frequency was not available, we estimated the allele frequencies using the UK Biobank data¹⁶.

The eQTL summary-level statistics were obtained from the CAGE data¹¹, consisting of 36,778 transcription phenotypes and ~8 million SNPs on 2,765 peripheral blood samples (of predominantly European ancestry). Transcription levels were measured using Illumina gene expression arrays. For replication in the retina, the summary cis-eQTL data were obtained from 523 postmortem retinas with ~ 9 million SNPs and 15,124 gene expression traits¹⁷, available in the Eye Genotype Expression (EyeGex) database (URLs). For replication in other multiple tissues, we used the GTEx v7 data, containing a set of cis-eQTL summary data across 48 human tissues (URLs). Transcription levels in both EyeGex and GTEx were measured by RNA-seq. The eQTL effects in all the three data sets were expressed in standard

deviation (SD) units of transcription levels.

SMR and HEIDI test for pleiotropic association

SMR and HEIDI analyses were developed to identify genes whose expression levels were associated with a complex trait because of pleiotropy/causality (i.e., the trait and gene expression are associated due to the same set of causal variants at a locus)¹². First, the SMR test takes the top associated cis-eQTL of the gene as an instrumental variable to test for association of a transcript (as an exposure) with AMD (as an outcome). An SMR estimate of the effect of gene expression on AMD is the ratio of the estimated effect of the instrument on a transcript (eQTL effect) and that on the disease (GWAS effect). The standard error (SE) of the SMR effect is computed using the Delta method, and the significance of the effect is assessed by the Wald test. To exclude the SMR associations due to linkage (i.e., the trait and gene expression are associated due to distinct set of causal variants in LD), the HEIDI analysis uses multiple SNPs in a cis-eQTL region to test against the null hypothesis that the trait is associated with gene expression because of the same set of underlying causal variants (pleiotropy/causality). Under the null, the SMR effects estimated using different eQTL SNPs in the cis region are expected to be the same. Significant heterogeneity in SMR effects detected at different SNPs in LD with the top associated cis-eQTL would be considered as linkage and rejected from the analysis.

Morpholino, mRNA rescue and overexpression experiments

For the *cnn2* mRNA rescue experiment, we generated zebrafish cDNA from total RNA using RT-PCR on a full-length *cnn2* fragment. For the *sarm1* mRNA rescue and *bloc1s1* overexpression study, we attained specific cDNA from the pUC57 vector cloned into template cDNA sequences of *sarm1* or *bloc1s1*, which were obtained through oligoribonucleotide synthesis (Sangon Biotech, Shanghai, China). The amplification primers of *cnn2* included the forward (5'-TAATACGACTCACTATAGGGGCCACCATGTCTTCGCAG-3') and the reverse (5'-TTAGTAATCTTGGCCGTCGTCCTGATAGC-3'); *sarm1* included the forward (5'-TAATACGACTCACTATAGGGGCCACCATGTTTTTGTCCCTCG-3') and the reverse (5'-CTACTTCTTTTGTGGCTCTTTTTTGTCCG-3'); *bloc1s1*, included the forward (5'-TAATACGACTCACTATAGGGGCCACCATGCTCTCGCGG-3') and the reverse (5'-TCATGTGGATGCCGGCTGGAC-3'); they all flank the T7 promoter sequence (5'-TAATACGACTCACTATAGGG-3') and enhancing sequence (Kozak). PCR template DNA was purified using the QIAquick PCR Purification Kit (Qiagen, Germany). Capped and tailed full-length mRNA was then synthesized using an mMESSAGE mMACHINE™ T7 ULTRA Transcription Kit (Invitrogen, Carlsbad, CA) before purification using the RNeasy Mini Kit (Qiagen, Germany) following the manufacturer's protocols. Rescue mRNAs were co-injected with MO into the one-cell stage embryos. For overexpression, corresponding mRNAs were injected into one- to two-cell stage embryos.

Measurement of eye parameters and body length

The eye parameter and body length measurements of 3 days post-fertilisation (dpf) embryos were assessed using stereomicroscopy (SZX116, OLYMPUS, Japan). Pictures of the vertical and lateral view of each larva were recorded by a microscopic camera. Axial length, eye area, and body length were quantified by built-in software (OLYMPUS cellsens standard, version 1.14). For data collection, 10-15 larvae were included in each group; experiments were replicated three times. Student's t-test was performed between controls and treatment conditions for each phenotype. Statistical differences were calculated and visualized by R software (version 3.5.3) and the ggplot2 package (version 3.1.0).

Visual behaviour experiments

Visual motor response (VMR) of 5 dpf was measured using a Zebrabox (VMR machine ViewPoint 2.0, France) to evaluate lights-ON and lights-OFF responses. All larvae with different treatments were separately placed in a 96-well plate with adequate water to ensure free activities (12 larvae for each treatment). The Zebrabox protocol was set to apply: 1) dark adaption for 3 hrs; 2) ON light for 30 mins; 3) OFF light for 30 mins; and 4) repeat step 2 and step 3 three times. Motor activities were recorded every second. The duration of 150 s (30 s before and 120 s after light switching) was used to evaluate the visual motor activities of larvae. Aggregate data of three repetitions were compiled and visualized in the figures. The area under the curve, calculated by R package MESS (Version 1.0), was used to quantify the overall motor response during 150 s of light alterations. Twelve injected larvae for each group were randomly selected for experiments routinely conducted between 11:00 and 17:00.

Real-time quantitative PCR

Zebrafish oculus was isolated from the control and experimental groups (n=30 pairs for each) at 3 dpf. Total RNA was then extracted with TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA). RNA concentrations were determined using a NanoDrop instrument (NanoDrop Technologies, Thermo, US). Following the manufacturer's instructions, purified RNA (500 ng) was used to generate cDNA using PrimeScript reverse transcriptase (TaKaRa, Dalian, China). Real-time quantitative PCR was performed through FastStart Universal SYBR Green Master (RocheApplied Science, Mannheim, Germany). Specific primers are provided in Supplementary Table 4. The relative expression levels were detected by the StepOne Plus TM Real-time PCR System (Life Technologies, Carlsbad, CA, USA) and calculated by the $2^{-\Delta\Delta CT}$ method. The fold change was compared to the standard MO control. All experiments were performed in triplicate.

Immunohistochemistry

For immunostaining purposes, morphants and control larvae at 3 dpf were fixed in 4% paraformaldehyde and were rinsed with 15% and 30% sucrose in PBS for dehydration. Zebrafish samples were then directly frozen in Richard-Allan Scientific™ Neg-50™. Cryosections of zebrafish eyes that were 18-μm were stained with zpr-1, zpr-2 and zpr-3 zebrafish-specific antibodies (1:400; provided by ZFIN) overnight at 4 °C. Alexa Fluor 594 anti-mouse secondary antibodies (1:400, provided by ZFIN) were used for

incubation in blocking solution for 2 hrs at room temperature. DAPI (4,6-diamidino-2-phenylindole) was counterstained for the cell nucleus. Coverslips were mounted, and a confocal microscope (TCS SP8, Leica, Germany) was used to analyse gene expression and retinal architecture.

URLs

AMD summary results: <http://amdgenetics.org/>
eQTL summary results: <http://cnsngenomics.com/software/smr/#DataResource>
SMR software: <http://cnsngenomics.com/software/smr>
EyeGex: <https://gtexportal.org/home/datasets>
Ensembl Orthologs: <http://asia.ensembl.org/index.html>
GeneCards Orthologs: <https://www.genecards.org/>

Acknowledgements

This research was supported by the Natural Science Foundation of China (81522014; 81970838), National Key R&D Program of China (2017YFA0105300), and Zhejiang Provincial Natural Science Foundation of China (LQ17H120005), Ministry of Education 111 project (D16011), the Australian National Health and Medical Research Council (1113400) and the Australian Research Council (FT180100186). This study makes use of data from the UK Biobank (project ID: 21497). A full list of acknowledgments of this data set can be found in Supplementary Note 2.

References

- DeAngelis, M. M. *et al.* Genetics of age-related macular degeneration (AMD). *Human molecular genetics* **26**, R45-r50, doi:10.1093/hmg/ddx228 (2017).
- Wong, W. L. *et al.* Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. *The Lancet. Global health* **2**, e106-116, doi:10.1016/s2214-109x(13)70145-1 (2014).
- Velez-Montoya, R. *et al.* Current knowledge and trends in age-related macular degeneration: genetics, epidemiology, and prevention. *Retina (Philadelphia, Pa.)* **34**, 423-441, doi:10.1097/iae.000000000000036 (2014).
- Klein, R. J. *et al.* Complement factor H polymorphism in age-related macular degeneration. *Science (New York, N.Y.)* **308**, 385-389 (2005).
- Fritsche, L. G. *et al.* A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. *Nature genetics* **48**, 134-143, doi:10.1038/ng.3448 (2016).
- Chen, W. *et al.* Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. *Proceedings of the National Academy of Sciences of the United States of America* **107**, 7401-7406, doi:10.1073/pnas.0912702107 (2010).
- Zhan, X. *et al.* Identification of a rare coding variant in complement 3 associated with age-related macular degeneration. *Nature genetics* **45**, 1375-1379, doi:10.1038/ng.2758 (2013).
- Fritsche, L. G. *et al.* Age-related macular degeneration: genetics and biology coming together. *Annual review of genomics and human genetics* **15**, 151-171, doi:10.1146/annurev-genom-090413-025610 (2014).
- Edwards, Stacey L., Beesley, J., French, Juliet D. & Dunning, Alison M. Beyond GWASs: Illuminating the Dark Road from Association to Function. *The American Journal of Human Genetics* **93**, 779-797, doi:10.1016/j.ajhg.2013.10.012 (2013).
- Wu, Y. *et al.* Integrative analysis of omics summary data reveals putative mechanisms underlying complex traits. *Nature communications* **9**, 918, doi:10.1038/s41467-018-03371-0 (2018).

479 11 Lloyd-Jones, L. R. *et al.* The Genetic Architecture of Gene Expression in Peripheral Blood. *American*
480 *journal of human genetics* **100**, 228-237, doi:10.1016/j.ajhg.2016.12.008 (2017).

481 12 Zhu, Z. *et al.* Integration of summary data from GWAS and eQTL studies predicts complex trait gene
482 targets. *Nature genetics* **48**, 481-487, doi:10.1038/ng.3538 (2016).

483 13 Gusev, A. *et al.* Integrative approaches for large-scale transcriptome-wide association studies. *Nature*
484 *genetics* **48**, 245-252, doi:10.1038/ng.3506 (2016).

485 14 Xue, A. *et al.* Genome-wide association analyses identify 143 risk variants and putative regulatory
486 mechanisms for type 2 diabetes. *Nature communications* **9**, 2941, doi:10.1038/s41467-018-04951-w
487 (2018).

488 15 Hauberg, M. E. *et al.* Large-Scale Identification of Common Trait and Disease Variants Affecting Gene
489 Expression. *The American Journal of Human Genetics* **100**, 885-894, doi:10.1016/j.ajhg.2017.04.016
490 (2017).

491 16 Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203-
492 209, doi:10.1038/s41586-018-0579-z (2018).

493 17 Ratnapriya, R. *et al.* Retinal transcriptome and eQTL analyses identify genes associated with age-related
494 macular degeneration. *Nature genetics*, doi:10.1038/s41588-019-0351-9 (2019).

495 18 Qi, T. *et al.* Identifying gene targets for brain-related traits using transcriptomic and methylomic data
496 from blood. *Nature communications* **9**, 2282, doi:10.1038/s41467-018-04558-1 (2018).

497 19 Lim, L. S., Mitchell, P., Seddon, J. M., Holz, F. G. & Wong, T. Y. Age-related macular degeneration. *Lancet*
498 *(London, England)* **379**, 1728-1738, doi:10.1016/s0140-6736(12)60282-7 (2012).

499 20 Myers, C. E. *et al.* Cigarette smoking and the natural history of age-related macular degeneration: the
500 Beaver Dam Eye Study. *Ophthalmology* **121**, 1949-1955, doi:10.1016/j.ophtha.2014.04.040 (2014).

501 21 Wu, J., Cho, E., Willett, W. C., Sastry, S. M. & Schaumberg, D. A. Intakes of Lutein, Zeaxanthin, and Other
502 Carotenoids and Age-Related Macular Degeneration During 2 Decades of Prospective Follow-up. *JAMA*
503 *ophthalmology* **133**, 1415-1424, doi:10.1001/jamaophthalmol.2015.3590 (2015).

504 22 Seddon, J. M. *et al.* Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular
505 degeneration. Eye Disease Case-Control Study Group. *Jama* **272**, 1413-1420 (1994).

506 23 Cheung, C. M. & Wong, T. Y. Is age-related macular degeneration a manifestation of systemic disease?
507 New prospects for early intervention and treatment. *Journal of internal medicine* **276**, 140-153,
508 doi:10.1111/joim.12227 (2014).

509 24 Battle, A., Brown, C. D., Engelhardt, B. E. & Montgomery, S. B. Genetic effects on gene expression across
510 human tissues. *Nature* **550**, 204-213, doi:10.1038/nature24277 (2017).

511 25 Roosing, S. *et al.* Disruption of the basal body protein POC1B results in autosomal-recessive cone-rod
512 dystrophy. *American journal of human genetics* **95**, 131-142, doi:10.1016/j.ajhg.2014.06.012 (2014).

513 26 Huang, X. F. *et al.* Mutation of IPO13 causes recessive ocular coloboma, microphthalmia, and cataract.
514 *Experimental & molecular medicine* **50**, 53, doi:10.1038/s12276-018-0079-0 (2018).

515 27 Zheng, S. S., Han, R. Y., Xiang, L., Zhuang, Y. Y. & Jin, Z. B. Versatile Genome Engineering Techniques
516 Advance Human Ocular Disease Researches in Zebrafish. *Frontiers in cell and developmental biology* **6**,
517 75, doi:10.3389/fcell.2018.00075 (2018).

518 28 Emran, F., Rihel, J. & Dowling, J. E. A behavioral assay to measure responsiveness of zebrafish to changes
519 in light intensities. *Journal of visualized experiments : JoVE*, doi:10.3791/923 (2008).

520 29 Tzima, E. *et al.* Transcriptional and Behavioral Responses of Zebrafish Larvae to Microcystin-LR Exposure.
521 *International journal of molecular sciences* **18**, doi:10.3390/ijms18020365 (2017).

522 30 Zhang, L. *et al.* Expression profiling of the retina of pde6c, a zebrafish model of retinal degeneration.
523 *Scientific data* **4**, 170182, doi:10.1038/sdata.2017.182 (2017).

524 31 Zhang, T., Zhang, N., Baehr, W. & Fu, Y. Cone opsin determines the time course of cone photoreceptor
525 degeneration in Leber congenital amaurosis. *Proceedings of the National Academy of Sciences of the*
526 *United States of America* **108**, 8879-8884, doi:10.1073/pnas.1017127108 (2011).

527 32 Nir, I., Agarwal, N. & Papermaster, D. S. Opsin gene expression during early and late phases of retinal
528 degeneration in rds mice. *Experimental eye research* **51**, 257-267, doi:10.1016/0014-4835(90)90022-m
529 (1990).

530 33 Cuneo, A., Powner, M. B. & Jeffery, G. Death by color: differential cone loss in the aging mouse retina.
531 *Neurobiology of aging* **35**, 2584-2591, doi:10.1016/j.neurobiolaging.2014.05.012 (2014).

532 34 Ferrington, D. A., Sinha, D. & Kaarniranta, K. Defects in retinal pigment epithelial cell proteolysis and the
533 pathology associated with age-related macular degeneration. *Progress in retinal and eye research* **51**,
534 69-89, doi:10.1016/j.preteyeres.2015.09.002 (2016).

535 35 Vösa, U. *et al.* Unraveling the polygenic architecture of complex traits using blood eQTL metaanalysis.

536 *bioRxiv*, 447367, doi:10.1101/447367 (2018).

537 36 Sumanas, S. & Larson, J. D. Morpholino phosphorodiamidate oligonucleotides in zebrafish: a recipe for

538 functional genomics? *Briefings in functional genomics & proteomics* **1**, 239-256,

539 doi:10.1093/bfpg/1.3.239 (2002).

540 37 Wei, K. *et al.* Developmental origin of age-related coronary artery disease. *Cardiovascular research* **107**,

541 287-294, doi:10.1093/cvr/cvv167 (2015).

542 38 Briana, D. D. & Malamitsi-Puchner, A. Developmental origins of adult health and disease: The metabolic

543 role of BDNF from early life to adulthood. *Metabolism: clinical and experimental* **81**, 45-51,

544 doi:10.1016/j.metabol.2017.11.019 (2018).